Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,414.77 6.23 0.04%
S&P 500 1,863.96 -0.89 -0.05%
NASDAQ 4,091.08 -4.43 -0.11%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,512.38 -3.89 -0.03%
TOPIX 1,171.40 -1.97 -0.17%
HANG SENG 22,760.24 64.23 0.28%

BioLineRx to Present at the 2012 Fifth Annual LD MICRO Conference in Los Angeles on December 5th



  BioLineRx to Present at the 2012 Fifth Annual LD MICRO Conference in Los
  Angeles on December 5th

Business Wire

JERUSALEM -- November 30, 2012

BioLineRx Ltd. (NASDAQ:BLRX) (TASE:BLRX), a biopharmaceutical development
company, today announced that its management team will be presenting at the
2012 Fifth Annual LD MICRO Conference at the Luxe Sunset Bel Air Hotel in Los
Angeles.

The Chief Executive Officer of BioLineRx, Dr. Kinneret Savitsky, and the
Company’s Chief Financial and Operating Officer, Mr. Philip Serlin, are
scheduled to present at 11:30 a.m. PT on Wednesday, December 5^th. The
presentation will be broadcast over the Internet as a "live" listen only
Webcast. To listen, please go to: webcast link.  For those unable to listen to
the live presentation, an archive of the event will also be available for 90
days.

Investors attending the conference that wish to meet with Dr. Savitsky or Mr.
Serlin for a one-on-one meeting should notify their LD Micro contact.

About BioLineRx

BioLineRx is a publicly-traded biopharmaceutical development company.
BioLineRx is dedicated to building a portfolio of products for unmet medical
needs or with advantages over currently available therapies. BioLineRx’s
current portfolio consists of six clinical stage candidates: BL-1020 for
schizophrenia is currently undergoing a Phase II/III study; BL-1040, for
prevention of pathological cardiac remodeling following a myocardial
infarction, which has been out-licensed to Ikaria Inc., is currently
undergoing a pivotal CE-Mark registration trial; BL-5010 for non-surgical
removal of skin lesions has completed a Phase I/II study; BL-1021 for
neuropathic pain is in Phase I development, BL-7040 for treating inflammatory
bowel disease (IBD) is currently undergoing a Phase II trial, and BL-8040 for
treating acute myeloid leukemia (AML) and other hematological cancers has
completed Phase I. In addition, BioLineRx has eight products in various
pre-clinical development stages for a variety of indications, including
central nervous system diseases, infectious diseases, cardiovascular and
autoimmune diseases.

BioLineRx’s business model is based on acquiring molecules mainly from
biotechnological incubators and academic institutions. The Company performs
feasibility assessment studies and development through pre-clinical and
clinical stages, with partial funding from the Israeli Government’s Office of
the Chief Scientist (OCS). The final stage includes partnering with medium and
large pharmaceutical companies for advanced clinical development (Phase 3) and
commercialization.

For more information on BioLineRx, please visit www.biolinerx.com.

Contact:

KCSA Strategic Communications
Garth Russell / Todd Fromer
1 212-896-1250 / 1 212-896-1250
grussell@kcsa.com / tfromer@kcsa.com
or
Tsipi Haitovsky
Public Relations
+972-3-6240871
tsipih@netvision.net.il
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement